Asthma, Smoking, Emotional Deficits (ASTADEM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69004
- Service de Pneumologie Hôpital de la Croix-Rousse
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women (> 18 years).
- Asthma (mild, moderate, severe).
- Beneficiary of social security
Exclusion Criteria:
- Pregnant women
- Patients who oppose their participation in the study
- Multiple drug users (psychoactive substances).
- Patients with severe psychiatric antecedents and comorbidities.
- Patients with cancer
- Patients with cognitive impairment
- Patients with speech, hearing, visual, and praxic disorders.
- Any chronic and especially respiratory pathology other than asthma (COPD, bronchiectasis), which can alter the study.
- Patients not speaking French
- Persons protected by law
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Asthma population
Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
|
The intervention will take place with patients followed for asthma at the Croix Rousse hospital.
Patients agreeing to participate in the study will come to the hospital for one hour and a half.
They will answer questionnaires and tests of drawing.
Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Poor control of asthma
Time Frame: During routine visit (one hour and a half)
|
The poor asthma control is defined by a score <20 on the ACT test
|
During routine visit (one hour and a half)
|
|
Emotional deficit such as alexithymia
Time Frame: During routine visit (one hour and a half)
|
Defined by a score ≥ 44 points/100 on the Toronto scale
|
During routine visit (one hour and a half)
|
|
Emotional deficit indicator traces
Time Frame: During routine visit (one hour and a half)
|
Identifying indicator traces of emotional deficits according to the dimensions defining the alexithymia on the test of the tree and the drawing of the person
|
During routine visit (one hour and a half)
|
|
Depression
Time Frame: During routine visit (one hour and a half)
|
Defined by a score ≥ 11 points on the HADS scale
|
During routine visit (one hour and a half)
|
|
Anxiety
Time Frame: During routine visit (one hour and a half)
|
Defined by a score ≥ 11 points on the HADS scale
|
During routine visit (one hour and a half)
|
|
Emotional valences
Time Frame: During routine visit (one hour and a half)
|
Defined by 8 scores distinct on Diener's subjective well-being scale
|
During routine visit (one hour and a half)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 69HCL17_0159
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
NCT07412769RecruitingAsthma in Children | Asthma Acute | Asthma Crisis | Asthma Childhood
-
NCT07261423RecruitingAsthma Exacerbation | Childhood Asthma | Air Pollution, Risk Reduction Behaviors | Asthma Control
-
NCT03277170WithdrawnAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; Status
-
NCT07582211Not yet recruitingAcute Asthma | Pediatric Asthma | Non-invasive Positive Pressure Ventilation | BiPAP
-
NCT03642418CompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
NCT06377345RecruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
NCT07489911RecruitingAsthma | Asthma Bronchiale | Asthma Patients
-
NCT07394127CompletedAsthma | Asthma Chronic | Asthma Control
-
NCT04480242Active, not recruitingAsthma in Children | Persistent Asthma | Asthma Exacerbation
Clinical Trials on Interview and tests of drawing.
-
NCT04180683CompletedDepressive Disorder | Depression | Neurocognitive Disorders | Dementia
-
NCT02134561Completed
-
NCT01518023CompletedDiabetes Mellitus | Gastric Cancer | Colorectal Cancer | Morbid Obesity | Prediabetes
-
NCT02218567Terminated
-
NCT01016028WithdrawnBreast Cancer | Colorectal Cancer | Myeloma | Chemotherapy-induced Peripheral Neuropathy
-
NCT05077696Not yet recruitingProgressive Motor Neuron Disease Without Definite Diagnosis